| Officer | Age | In this role | Source |
|---|---|---|---|
|
Shalabh Gupta, M.D.
Also a director
President, Chief Executive Officer and Chairman of the Board
|
53 | Not stated | |
|
John Townsend
Chief Financial Officer
|
64 |
Since 2021
5 years
|
|
|
Pramod Gupta, Ph.D.
EVP, Pharmaceuticals and BD
Title from the Form 4/A dated May 14, 2026
|
66 | Not stated | |
|
Doug Jermasek
Executive Vice President, Corporate Strategy
|
65 |
Since 2021
5 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Sep 29, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Shalabh Gupta
CEO
|
53 |
2016
10 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Sandeep Laumas
|
58 | Not stated | Independent |
Audit Committee · Chair
Compensation Committee
Nominating and Governance Committee
|
BioXcel Therapeutics Inc. | $154,486 | |
|
Meredith S. Manning
Joined Oct 1, 2026
|
- | - | Independent |
Audit Committee
Compensation Committee
Nominating and Corporate Governance Committee · Chair
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 30, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...